(NYSEMKT: SER) Serina Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.15%.
Serina Therapeutics's earnings in 2026 is -$27,363,000.On average, 3 Wall Street analysts forecast SER's earnings for 2026 to be -$42,399,541, with the lowest SER earnings forecast at -$45,827,001, and the highest SER earnings forecast at -$39,057,103. On average, 2 Wall Street analysts forecast SER's earnings for 2027 to be -$28,176,910, with the lowest SER earnings forecast at -$27,339,972, and the highest SER earnings forecast at -$29,292,827.
In 2027, SER is forecast to generate -$30,995,930 in earnings, with the lowest earnings forecast at -$34,630,632 and the highest earnings forecast at -$27,339,972.